- Wegovy and Zepbound covered for FDA-labeled indications with PA
- Ozempic and Mounjaro covered only for type 2 diabetes
- Step therapy with prior anti-obesity drugs typically required
- Self-funded employer plans may exclude anti-obesity coverage entirely
How Aetna structures GLP-1 coverage
Aetna maintains separate formulary tiers and prior-authorization rules for each GLP-1. The two semaglutide products (Wegovy and Ozempic) and the two tirzepatide products (Zepbound and Mounjaro) are not interchangeable on Aetna's formulary — the brand and indication on the prescription have to match the covered use.
Wegovy on Aetna
Covered for: (1) chronic weight management in adults with BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity; (2) cardiovascular risk reduction in adults with established CVD and overweight or obesity; (3) adolescents 12+ with obesity. Prior authorization requires documented BMI, comorbidity list, prior weight-management interventions, and a treatment plan. Re-authorization at 6 months requires ≥ 5% weight loss.
Zepbound on Aetna
Covered for: (1) chronic weight management with the same BMI criteria as Wegovy; (2) moderate-to-severe obstructive sleep apnea with obesity (added 2025 after FDA approval). The OSA indication is a major coverage path for patients whose Aetna employer plan excludes weight-loss drugs.
Ozempic and Mounjaro on Aetna
Both are covered only for type 2 diabetes (their FDA-labeled use). Prior authorization typically requires an A1c ≥ 6.5%, documented metformin trial (or contraindication), and adult age. Off-label weight-loss prescriptions are denied — patients seeking GLP-1 for weight loss without T2D should pursue Wegovy (semaglutide) or Zepbound (tirzepatide).
Step therapy requirements
For obesity indications, Aetna typically requires ≥ 6 months of documented lifestyle modification (diet, exercise, behavioral counseling) and at least one prior trial of phentermine, orlistat, Contrave (naltrexone/bupropion), or Qsymia (phentermine/topiramate).
Documented intolerance, contraindication, or treatment failure on prior anti-obesity drugs satisfies the step-therapy requirement without requiring a current trial.
Common Aetna denial reasons & fixes
'Plan exclusion — anti-obesity drugs': your employer chose not to cover weight-loss medications. Pivot to a covered indication (CVD risk for Wegovy, OSA for Zepbound, T2D for Ozempic/Mounjaro) if clinically applicable.
'Step therapy not met': resubmit with prescription records or chart notes documenting prior phentermine/orlistat/Contrave/Qsymia trial.
'BMI not documented': have the clinic measure and record BMI at the most recent visit, then resubmit.
'Re-authorization weight loss insufficient': if you have not lost ≥ 5% body weight by month 6, document adherence, dose titration history, and any clinical factors (other medications, hypothyroidism, etc.) supporting continued treatment.
Filing an Aetna appeal
Aetna allows 180 days from the denial date for internal appeals. Submit via the appeals address listed on the denial letter or through the Aetna member portal. Include the prescriber's letter of medical necessity, the documentation that was missing from the original PA, and a copy of the denial letter. Internal appeals are decided within 30 days (or 72 hours if expedited). If denied internally, you can request an external review through your state's independent review organization.
Frequently asked questions
Get an Aetna-specific approval score
Answer a few questions about your Aetna plan and clinical profile — receive a personalized approval-likelihood score and prior-authorization checklist.
Educational guidance only — not medical or legal advice.